Skip to main content
Premium Trial:

Request an Annual Quote

Donald Halbert Joins Iconix from Abbott as Excecutive VP R&D, Steven Salzberg to Leave TIGR to Direct Bioinformatics Center at the University of Maryland; Cliff Turner New President of NextGen Sciences US, and Others

Donald Halbert has joined Iconix Pharmaceuticals as executive vice president of research and development, the company said yesterday. He comes to Iconix from Abbott Laboratories, where he was director of genomics, proteomics, and bioinformatics in the global pharmaceutical research and development group. In addition, he was chairman of the Abbott-Iconix scientific advisory committee, overseeing the two companies' 2003 alliance. Previously, he held scientific and management positions at Becton Dickinson. Halbert has a PhD in molecular virology from WashingtonUniversity in St. Louis.


Steven Salzberg, senior director of bioinformatics at the Institute for Genomic Research (TIGR), will be leaving his post this summer to serve as director of the center for bioinformatics and computational biology at the Universityof Maryland, according to BioInform, a GenomeWeb newsletter.


Cliff Turner has been appointed as president of NextGen Sciences Inc, the wholly-owned USsubsidiary of NextGen Sciences in the UK, the company said today. He replaces Andrew Creasey, who will remain a company consultant. Turner will operate NextGen's new USoffice in Illinois. Previously, he was director of sales and marketing development at Nanosphere and held positions at Affymetrix and Life Technologies, now part of Invitrogen. He has an undergraduate degree in biology from the Universityof Illinoisand an MS degree in immunology and microbial genetics from Northern Illinois University.


Graham Fleming will be the new deputy director of Lawrence Berkeley National Laboratory, Berkeley Lab said last week. He will replace Pier Oddone, who will become director of the Fermi National Accelerator Laboratory in July. Fleming has been the lab's physical biosciences division director. He holds a PhD in chemistry from the Universityof London.


Janet Thornton has won this year's senior scientist accomplishment award and Ewan Birney the Overton prize from the International Society for Computational Biology, ISCB and the European Bioinformatics Institute said on Monday.


Thornton, who has been director of EBI since 2001 as well as coordinator of the BioSapiens network of excellence, receives the award for outstanding and seminal research contributions to the field of structural bioinformatics. She is also the founding chief scientific officer of Inpharmatica.


Birney is honored for his work on Ensembl, the genome browser. He has been a coordinator of EBI's contributions to Ensembl since 2000. He is also a co-leader of the open-source project Bioperl and president of the Open Bioinformatics Foundation. Birney holds an undergraduate degree in biochemistry from OxfordUniversityand obtained a PhD in gene prediction from the Wellcome Trust Sanger Institute.


James Watson will receive the 2005 Othmer Gold Medal from the Chemical Heritage Foundation, the foundation said last week. He is honored for "his scientific imagination and intellectual drive [that] have opened the way to countless new therapies and the possibility of longer, healthful lives," according to CHF. Watson, a Nobel laureate and co-discoverer of the structure of DNA, holds a PhD in zoology from IndianaUniversity and a BS in zoology from the Universityof Chicago. He will receive the award at a ceremony in Philadelphiaon June 9.


Promoted? Changing jobs? GenomeWeb News wants to know. E-mail us at [email protected]to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.